A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors
Published inCancer chemotherapy and pharmacology, vol. 81, no. 1, p. 73-80
Publication date2017-11-03
First online date2017-11-03
Keywords
- Dovitinib
- Drug–drug interaction
- Fluvoxamine CYP1A2
- TKI258
Affiliation entities
Research groups
Citation (ISO format)
DE WEGER, Vincent A. et al. A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. In: Cancer chemotherapy and pharmacology, 2017, vol. 81, n° 1, p. 73–80. doi: 10.1007/s00280-017-3469-4
Main files (1)
Article (Published version)
Identifiers
- PID : unige:175787
- DOI : 10.1007/s00280-017-3469-4
- PMID : 29101463
Additional URL for this publicationhttp://link.springer.com/10.1007/s00280-017-3469-4
Journal ISSN0344-5704
